RELMADA THERAPEUTICS, INC. Amortization of Debt Discount (Premium)
RELMADA THERAPEUTICS, INC. (RLMD) reported Amortization of Debt Discount (Premium) of $661.17 thousand for the 12-month period ending 2019-06-30, per its 10-K filed 2021-03-24.
Discontinued › Cash Flow › Operating Activities
us-gaap:AmortizationOfDebtDiscountPremium · last filed 2021-03-24
- RELMADA THERAPEUTICS, INC. amortization of debt discount (premium) for the quarter ending 2019-06-30 was $1.00, a 100.00% decline year-over-year.
- RELMADA THERAPEUTICS, INC. amortization of debt discount (premium) for the quarter ending 2019-03-31 was $0.00, a 100.00% decline year-over-year.
- RELMADA THERAPEUTICS, INC. amortization of debt discount (premium) for the quarter ending 2018-12-31 was $124.65K, a 39.19% decline year-over-year.
- RELMADA THERAPEUTICS, INC. amortization of debt discount (premium) for the quarter ending 2018-09-30 was $536.52K, a 18932.28% increase year-over-year.
- RELMADA THERAPEUTICS, INC. amortization of debt discount (premium) for fiscal 2019 was $661.17K, a 35.76% decline from fiscal 2018.
- RELMADA THERAPEUTICS, INC. amortization of debt discount (premium) for fiscal 2018 was $1.03M.
- RELMADA THERAPEUTICS, INC. amortization of debt discount (premium) for fiscal 2013 was $118.64K.
| Period end | Amortization of Debt Discount (Premium) 3 month | Amortization of Debt Discount (Premium) 6 month | Amortization of Debt Discount (Premium) 9 month | Amortization of Debt Discount (Premium) 12 month | Amortization of Debt Discount (Premium) 115 month | Amortization of Debt Discount (Premium) 118 month |
|---|---|---|---|---|---|---|
| 2019-06-30 | $1.00 derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-24 | $1.00 derived: sum of 2 quarters · filed 2021-03-24 | $124.65K derived: sum of 3 quarters · filed 2021-03-24 | $661.17K 10-K · filed 2021-03-24 | ||
| 2019-03-31 | $0.00 derived: 10-Q 9 month − 10-KT 6 month · filed 2019-05-15 | $124.65K derived: sum of 2 quarters · filed 2020-03-26 | $661.17K 10-Q · filed 2019-05-15 | $1.19M derived: sum of 4 quarters · filed 2020-03-26 | ||
| 2018-12-31 | $124.65K derived: 10-KT 6 month − 10-Q 3 month · filed 2020-03-26 | $661.17K 10-KT · filed 2020-03-26 | $1.19M derived: sum of 3 quarters · filed 2020-03-26 | $1.48M derived: sum of 4 quarters · filed 2020-03-26 | ||
| 2018-09-30 | $536.52K 10-Q · filed 2019-11-13 | $1.06M derived: sum of 2 quarters · filed 2020-03-26 | $1.36M derived: sum of 3 quarters · filed 2020-03-26 | $1.56M derived: sum of 4 quarters · filed 2020-03-26 | ||
| 2018-06-30 | $527.98K derived: 10-KT 12 month − 10-Q 9 month · filed 2020-03-26 | $821.40K derived: sum of 2 quarters · filed 2020-03-26 | $1.03M derived: sum of 3 quarters · filed 2020-03-26 | $1.03M 10-KT · filed 2020-03-26 | ||
| 2018-03-31 | $293.42K derived: 10-Q 9 month − 10-Q 6 month · filed 2019-05-15 | $498.38K derived: sum of 2 quarters · filed 2019-05-15 | $501.20K 10-Q · filed 2019-05-15 | |||
| 2017-12-31 | $204.96K derived: 10-Q 6 month − 10-Q 3 month · filed 2019-02-13 | $207.78K 10-Q · filed 2019-02-13 | ||||
| 2017-09-30 | $2.82K 10-Q · filed 2018-11-13 | |||||
| 2014-06-30 | $242.44K derived: 10-K 6 month − 8-K 3 month · filed 2015-09-11 | $327.78K 10-K · filed 2015-09-11 | $394.80K derived: sum of 3 quarters · filed 2015-09-11 | $415.25K derived: sum of 4 quarters · filed 2015-09-11 | ||
| 2014-03-31 | $85.34K 8-K · filed 2014-05-27 | $152.36K derived: sum of 2 quarters · filed 2015-02-13 | $172.82K 10-Q · filed 2015-05-15 | $203.98K 8-K · filed 2014-05-27 | ||
| 2013-12-31 | $67.02K derived: 10-Q 6 month − 10-Q 3 month · filed 2015-02-13 | $87.48K 10-Q · filed 2015-02-13 | $118.64K 10-K · filed 2015-09-11 | $118.64K 8-K · filed 2014-05-27 | ||
| 2013-09-30 | $20.46K 10-Q · filed 2014-11-07 | |||||
| 2013-03-31 | $15.85K 8-K · filed 2014-05-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| Turn Therapeutics Inc. (TTRX) | United States | $0.397B | -25.68 |
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |